This statistic displays the median length of time that orphan and non-orphan products are in phase III trial, as of 2015. Orphan drugs were in phase III trials for a median of 2.89 years. Orphan drugs are used to target rare diseases or disorders, which in the United States is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the United States through the Orphan Drug Act of 1983.
Median phase III trial length for orphan and non-orphan drugs as of 2015
(in years)
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Statistics on "Pharmaceutical industry in the Netherlands"
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Evaluate. (October 30, 2015). Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years) [Graph]. In Statista. Retrieved February 21, 2020, from https://www.statista.com/statistics/373393/phase-iii-trial-length-for-orphan-and-non-orphan-drugs/
Evaluate. "Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years)." Chart. October 30, 2015. Statista. Accessed February 21, 2020. https://www.statista.com/statistics/373393/phase-iii-trial-length-for-orphan-and-non-orphan-drugs/
Evaluate. (2015). Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years). Statista. Statista Inc.. Accessed: February 21, 2020. https://www.statista.com/statistics/373393/phase-iii-trial-length-for-orphan-and-non-orphan-drugs/
Evaluate. "Median Phase Iii Trial Length for Orphan and Non-orphan Drugs as of 2015 (in Years)." Statista, Statista Inc., 30 Oct 2015, https://www.statista.com/statistics/373393/phase-iii-trial-length-for-orphan-and-non-orphan-drugs/
Evaluate, Median phase III trial length for orphan and non-orphan drugs as of 2015 (in years) Statista, https://www.statista.com/statistics/373393/phase-iii-trial-length-for-orphan-and-non-orphan-drugs/ (last visited February 21, 2020)
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.
